IRVINE, Calif., March 3, 2016 /PRNewswire/ -- Cryoport, Inc.
(NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics
company, today announced that it will be supporting the cryogenic
logistics requirements of ImmunoCellular Therapeutics' (NYSE MKT:
IMUC) ("ImmunoCellular") registrational Phase III glioblastoma
clinical trial across 120 sites in North
America and Europe. This
clinical trial is designed to evaluate the safety and efficacy of
ImmunoCellular's lead product candidate ICT-107, a patient-derived
dendritic cell-based immunotherapy.
Anthony Gringeri,
ImmunoCellular's Senior Vice President, Strategic Resources,
commented, "We chose to partner with Cryoport for the
registrational trial of ICT-107 because of their cold chain
logistics expertise and proven ability to manage the challenges of
transporting valuable, temperature-sensitive cryogenically frozen
materials. Of additional significance is their specialized
logistics operating platform for the timely and secure delivery of
our immunotherapy to the large number of patients participating in
our trial in the US, Canada and
Europe."
ImmunoCellular's ICT-107 immunotherapy targets six different
antigens, peptides that are tumor markers, associated with the
aggressive cancer of the brain, glioblastoma. More than 400
patients with newly diagnosed glioblastoma will be enrolled across
120 sites to participate in the trial. The regimen in the
Phase III trial is standard of care plus or minus ICT-107
immunotherapy. The regimen includes induction immunotherapy
(4 doses in month 1) and maintenance (monthly doses through month
12 or progression).
Jerrell Shelton, Chief Executive
Officer of Cryoport, Inc. commented, "Our agreement with
ImmunoCellular Therapeutics marks a substantial milestone in
Cryoport's history as it is one of the largest volume trials we
have supported. We are delighted that our advanced cryogenic
logistics solutions will play an integral role in the execution of
this Phase III trial. We will ensure the successful delivery of
ImmunoCellular's immune-based therapy to the 120 sites located in
North America and Europe as we employ our technology based
solutions. With this partnership, Cryoport now supports 64 clinical
trials worldwide, ten of which are Phase III trials."
"The biotech industry continues to develop advanced biologic and
immunotherapeutic solutions that are sensitive to their environment
and require the maintaining of specific temperatures during storage
and transit. As these therapies have moved from the
development stage and into the clinic, the need for a safe,
effective and consistent way to transport them has become clearer
to everyone in the industry. We are confident that our track record
makes Cryoport an indispensable resource for the advancement of the
biologics market," concluded Mr. Shelton.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics
solutions to the life sciences industry through its purpose-built
proprietary packaging, information technology and specialized cold
chain logistics expertise. The Company provides leading edge
logistics solutions for biologic materials, such as
immunotherapies, stem cells, CAR-T cells and reproductive cells for
clients worldwide. Cryoport actively supports points-of-care,
CRO's, central laboratories, pharmaceutical companies, contract
manufacturers and university researchers. For more information,
visit www.cryoport.com.
To download Cryoport's investor relations app, which
offers access to SEC documents, press releases,
videos, audiocasts and more, please click to download
from your iPhone and iPad or Android mobile
device.
Forward Looking Statements
Statements in this news release which are not purely
historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the company's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
company's cash flow, market acceptance risks, and technical
development risks. The company's business could be affected by a
number of other factors, including the risk factors listed from
time to time in the company's SEC reports including, but not
limited to, the annual report on Form 10-K for the year ended
March 31, 2015. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. Cryoport, Inc.
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
Logo -
http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cryoport-supports-immunocellular-therapeutics-120-site-phase-iii-clinical-trial-with-cold-chain-logistics-300230317.html
SOURCE Cryoport, Inc.